We should note that differential regulation of IFN response genes has been observed in many human malignancies, including leukemia [21], ovarian cancer [23], gastric cancer [14], lung cancer [24], colon cancer [25], and breast cancer [26] and that high expression of ISGs is associated with poor clinical outcome [14]. This evidence concerns the gene IFNA1 and malignant colon neoplasm.